Articles > Popular publications > PR Newswire press releases > January-March 2006 > Wednesday, February 15

Article: VaxGen Presents New Smallpox Vaccine Data at ASM Biodefense Research Meeting.

Article from:
PR Newswire
Article date:
February 15, 2006
Copyright

BRISBANE, Calif., Feb. 15 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN.PK) today announced new non-clinical and clinical data from studies of the company's attenuated smallpox vaccine candidate, LC16m8, which indicate that the vaccine may represent a viable replacement for the conventional smallpox vaccine currently in the U.S. Strategic National Stockpile. The data are being presented at this week's American Society of Microbiology (ASM) Biodefense Research Meeting in Washington, DC.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

VaxGen is developing LC16m8 for use in the United States and elsewhere in partnership with ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: VaxGen Begins Clinical Development of its Attenuated ...

  
  PR Newswire; 
  October 20, 2004 ;  
  
  
 
  700+ words
... ... immune response of its attenuated smallpox vaccine candidate, LC16m8 ... the most appropriate attenuated smallpox vaccine for use in the general ... emergency stockpile of attenuated smallpox vaccine and to license the product ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: FDA Clears VaxGen's IND for an Attenuated Smallpox ...

  
  PR Newswire; 
  September 7, 2004 ;  
  
  
 
  700+ words
... ... interest in acquiring an emergency stockpile of an attenuated smallpox vaccine(1) and licensing the product for commercial ... billion to establish and maintain a stockpile of attenuated smallpox vaccine over a 10-year period. The IND clears the ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: FDA clears IND for an attenuated smallpox ...

  
  Bioterrorism Week; 
  October 4, 2004 ;  
  
  
 
  700+ words
... ... interest in acquiring an emergency stockpile of an attenuated smallpox vaccine and licensing the product for commercial sales ... billion to establish and maintain a stockpile of attenuated smallpox vaccine over a 10-year period. The IND clears the ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: VaxGen Phase I/II Study of Attenuated Smallpox ...

  
  PR Newswire; 
  July 11, 2005 ;  
  
  
 
  700+ words
... ... immune response to its attenuated smallpox vaccine candidate, LC16m8. LC16m8 ... national stockpile of smallpox vaccine. Data from this trial ... Prize: Development of the Attenuated Smallpox Vaccine, LC16m8, Produced by ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Clinical development begun to study attenuated ...

  
  TB & Outbreaks Week; 
  November 16, 2004 ;  
  
  
 
  700+ words
... ... evaluate the safety and immune response of its attenuated smallpox vaccine candidate, LC16m8. One of 4 clinical sites ... interest in acquiring an emergency stockpile of attenuated smallpox vaccine and to license the product for commercial sales ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Five Abstracts Related to VaxGen's Smallpox Vaccine ...

  
  PR Newswire; 
  January 17, 2006 ;  
  
  
 
  700+ words
... ... Safety and Immunogenicity of Attenuated Smallpox Vaccine, LC16m8: Results from a Phase 2 Study -- Clinical Evaluation of Attenuated Smallpox Vaccine LC16m8 in Japan -- Attenuated Smallpox Vaccine LC16m8 Protects Mice from High ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: VaxGen and Kaketsuken Finalize Commercial Terms For ...

  
  PR Newswire; 
  December 2, 2003 ;  
  
  
 
  700+ words
... ... contracts for the purchase of attenuated smallpox vaccine. According to estimates ... LC16m8, is the only attenuated smallpox vaccine to have been licensed ... for the purchase of an attenuated smallpox vaccine. About VaxGen VaxGen ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Acambis announces significant progress on its MVA smallpox ...

  
  Internet Wire; 
  April 28, 2005 ;  
  
  
 
  700+ words
... ... Vaccinia Ankara ("MVA") attenuated smallpox vaccine, MVA3000, with results ... for whom the traditional smallpox vaccine is contraindicated, such ... procure a stockpile of an attenuated smallpox vaccine, such as MVA3000, as ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives